Nearly half of patients with positive lung cancer screening findings delay follow-up care
“Key takeaways: Delaying follow-up after receipt of positive lung cancer screening findings was relatively common. Patients with lung cancer had a high likelihood of clinical upstaging if they delayed follow-up.”
Lung Cancer Survivors and Caregivers Take Their Stories to Capitol Hill to Advocate for Lifesaving Research and Public Health Funding
“WASHINGTON, March 18, 2024 /PRNewswire/ — On Wednesday, March 20, LUNG FORCE Heroes—people living with lung cancer, their loved ones and advocates from across the country—will travel to Washington, D.C. to advocate for lifesaving research and public health funding. As a part of the American Lung Association LUNG FORCE Advocacy Day, the advocates will meet with members of Congress to share their stories, and ask them to support $51.3 billion in research funding for the National Institutes of Health (NIH) and $11.6 billion in funding for the Centers for Disease Control and Prevention (CDC).”
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
“MENLO PARK, Calif. & CAMBRIDGE, England–(BUSINESS WIRE)– GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN), will have their samples tested using GRAIL’s novel risk classification test on its Methylation Platform. This assay has been validated for recurrence risk classification in newly diagnosed Stage I lung adenocarcinoma.”
Early Onset of Lung Cancer in Small Areas as a Signature of Point Pollution Sources
“At a small-area scale, the detrimental effect of air pollution on lung cancer is challenging to identify and measure due to the potentially scattered detection of pollutants and/or limited statistical power of available indicators. A novel method is presented to detect and quantify the detrimental impact of pollution in small areas by employing the early onset of lung cancer as a signature of pollution. Early-onset lung cancer may speed up the investigation of potential environmental hazards in a specific area, enabling public health officials or citizen committees to carry out geographical analyses.”
FDA Accepts NDA for Ensartinib in Metastatic ALK-Positive NSCLC
“The regulatory agency set an action date of December 28, 2024 for ensartinib as a treatment for those with ALK-positive non–small cell lung cancer.”
Study Reveals New Insights Into Immune System Role in Lung Cancer Risk
“Recent developments in cancer research have highlighted the vital role of the immune system, particularly in the notable successes of cancer immunotherapy. Now, a paradigm-shifting study led by researchers at the Icahn School of Medicine at Mount Sinai in New York in collaboration with the University of Helsinki, Massachusetts General Hospital, and the Broad Institute of MIT and Harvard sheds light on how variations in immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening.”
Lung Cancer Replaces Breast Cancer as Most Common Form Among Chinese Women
“(Yicai) March 14 — Lung cancer has surpassed breast cancer as the most frequent type of malignant tumor among Chinese women amid the aging population. In 2022, China had 402,000 women with lung cancer and 357,000 people with breast cancer, according to the most recent report by the National Cancer Center. The nation recorded almost 1.1 million new lung cancers, making up 22 percent of all new cases of diseases linked to abnormal cell growth.”
Immunotherapy Trials for Metastatic NSCLC: FDA Pooled Analysis
“In a U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Bernardo Haddock Lobo Goulart, MD, and colleagues found that response rate and progression-free survival were only moderately correlated with overall survival in first-line immunotherapy trials for metastatic non–small cell lung cancer (NSCLC).”
